Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16584
Country/Region: South Africa
Year: 2016
Main Partner: Beyond Zero
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $2,148,602 Additional Pipeline Funding: $4,272,739

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $489,041
Care: Orphans and Vulnerable Children (HKID) $377,485
Care: TB/HIV (HVTB) $830,282
Care: Pediatric Care and Support (PDCS) $225,896
Laboratory Infrastructure (HLAB) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $225,898
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 13,757
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 13,757
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 148,647
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 99,064
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 275,233
HTS_TST Service Delivery Point (Facility): Index testing 2017 41,316
HTS_TST Service Delivery Point (Facility): Inpatient 2017 27,536
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 13,776
HTS_TST Service Delivery Point (Facility): Other PITC 2017 27,536
HTS_TST Service Delivery Point (Facility): Outpatient 2017 13,776
HTS_TST Service Delivery Point (Facility): Pediatric 2017 13,776
HTS_TST Service Delivery Point (Facility): PMTCT 2017 41,324
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 41,074
HTS_TST Service Delivery Point (Facility): VCT 2017 41,325
HTS_TST Service Delivery Point (Facility): VMMC 2017 14,006
HTS_TST Sum of Aggregated Age/Sex <15 2017 27,514
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 247,711
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 275,225
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 4,095
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 4,095
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 45,235
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 31,049
OVC_SERV Age/Sex: 18+ Female 2017 799
OVC_SERV Age/Sex: 18+ Female 2017 381
OVC_SERV Age/Sex: 18+ Male 2017 797
OVC_SERV Age/Sex: 18+ Male 2017 380
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 1,861
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 891
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 5,318
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 2,543
OVC_SERV Sum of Age/Sex disaggregates 2017 1,596
OVC_SERV Sum of Age/Sex disaggregates 2017 761
PMTCT_ART Already on ART at beginning of current pregnancy 2017 5,369
PMTCT_ART New on ART 2017 2,416
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 38,423
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 3,833
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 3,835
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 56
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 56
PMTCT_EID Sum of Infant Age disaggregates 2017 7,668
PMTCT_STAT By: Known positives at entry 2017 11,176
PMTCT_STAT By: Number of new positives identified 2017 5,770
PMTCT_STAT Number of new ANC and L&D clients 2017 39,205
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 38,423
PMTCT_STAT Sum of Positives Status disaggregates 2017 16,946
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 391
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3,459
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 315
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,291
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 7,136
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 6,462
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 101,813
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 5,110
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 8
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 10,219
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 5
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 88,799
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 145
TB_SCREENDX Screen Results: Screened Positive for TB 2017 102,105
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 10,636
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 10,635
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 115,872
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 76,573
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 212,713
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 606
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 6,454
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 607
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,299
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 11,951
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 12,532
TX_CURR Aggregated Age/Sex: <15 Female 2017 10,123
TX_CURR Aggregated Age/Sex: <15 Male 2017 10,121
TX_CURR Aggregated Age/Sex: 15+ Female 2017 109,292
TX_CURR Aggregated Age/Sex: 15+ Male 2017 72,866
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 202,540
TX_CURR Sum of Aggregated Age/Sex <15 2017 20,244
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 182,158
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 202,402
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2,734
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 2,734
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 29,509
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 19,670
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 54,643
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 54,647
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 182,673
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 164,034
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 8,204
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 8,204
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 88,573
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 59,055
TX_PVLS Numerator: Indication: Routine 2017 131,223
TX_PVLS Numerator: Indication: Targeted 2017 32,810
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 9,134
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 9,134
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 5
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 98,688
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 65,777
TX_PVLS_den Denominator: Indication: Routine 2017 146,217
TX_PVLS_den Denominator: Indication: Targeted 2017 36,480
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,707
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,707
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 61,629
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 50
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 41,071
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 32
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 113,966
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 121,305
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,057
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,057
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 66,236
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 42,918
Cross Cutting Budget Categories and Known Amounts Total: $1,308,771
Gender: Gender Based Violence (GBV) $100,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Capacity building
Post GBV Care
Collection and Use of Gender-related Strategic Information
Capacity building
Human Resources for Health $1,208,771